The following article was reprinted from The Progressive magazine with their permission and was written by Drs. Ida Helander and Steffie Woolhandler.

The rightward drift of the Democratic Party is nowhere more evident than in health care. In September, Bill Bradley, the former Democratic Senator from New Jersey and current Presidential candidate, declared his support for health reforms previously espoused by the ultraconservative Heritage Foundation. Bradley's plan is at its core profoundly reactionary, a vehicle for the Heritage Foundation's explicit agenda of "rolling back the welfare state."

Bradley's plan has already been endorsed by Chip Kahn, president of the powerful lobbying group the Health Insurance Association of America. And little wonder: Insurance companies and HMOs stand to gain billions of tax dollars from the Bradley plan, while Americans would still have no right to health care.

Bradley has impressed many with his ideas on race (and his jump shot). Yet his health proposal is so shameless in its $200 billion transfer of tax dollars to the private insurance industry that it might have made Richard Nixon blush. At a time when the possibilities for progressive reform seem bright, why are Bradley's health care proposals so backward?

Bradley has compared his proposal for the 11.1 million uninsured children to the Medicare program for seniors. This is nonsense. Medicare has guaranteed seniors basic health coverage for more than 30 years. Bradley's proposal is a mandate that parents buy their children private insurance. Admonishing parents to buy private coverage—even if such coverage were affordable and available (which it's not)—is a long way from guaranteeing kids coverage.

Bradley's plan relies on tax credits and a new federal bureaucracy to help poor families afford children's coverage. The subsidies would tempt employers to drop coverage of employees and their children but wouldn't be adequate to help many low- and middle-income fami-
lies buy private coverage. This is exactly what happened with the federal Children's Health Insurance Plan, the most recent incremental effort to increase coverage. In 1998 alone, the number of uninsured children rose 330,000, following rises of 188,000 in 1997 and 755,000 in 1996.

Bradley also proposes privatizing Medicaid, the current government insurance program that covers some of the poor and the disabled, as well as nursing home costs for poor seniors. The $193 billion in current Medicaid spending would go to private insurers. The nonelderly Medicaid recipients would get a voucher to purchase private coverage from plans participating in the Federal Employees Health Benefits program. Bradley would also offer tax credits to the uninsured to buy into that program.

As for the poor elderly who receive help from Medicaid with nursing home and long term care costs, Bradley would simply end 30 years of joint state and federal responsibility for their care and turn this over to the states completely (just in time for the boomers' retirement). Bradley would do the same for the disabled, risking the loss of the safety net for this vulnerable community.

With premiums rising at 8 percent per year, poor adults with Bradley's fixed tax subsidies or skimpy vouchers would be able to afford only the cheapest plans (mainly HMOs) in the Federal Employees Health Benefits Program, not the high-end coverage that members of Congress receive. Many millions of uninsured would continue to fall through the cracks. As with children, the tax subsidies for adults are inadequate to cover all the uninsured but might encourage employers to drop coverage to low-income workers.

For seniors, Bradley would create an optional prescription drug benefit to cover medication costs over $500 annually. Seniors would have to sign up and pay an extra premium for this modest benefit. Bradley's tepid proposal barely scratches the surface of that problem.

The Heritage Foundation must be flattered by Bradley's adoption of its ideas. For years, that foundation has pushed a similar plan for privatizing Medicare in an attempt to reduce public control while directing tax dollars to private insurers. Heritage scholars argue that consumers will choose the most efficient private plans and that competition in the market will reduce costs.

However the evidence from seniors who have opted for HMOs is that private plans are actually more costly than traditional coverage. The U.S. General Accounting Office (GAO) found that Medicare lost $1.3 billion in 1998 by enrolling seniors in HMOs.

In the past two years alone, Medicare HMOs have dumped 750,000 seniors who proved unprofitable. HMOs have recruited seniors by routinely misleading them about benefits. This year, Medicare HMOs are dramatically scaling back the prescription drug coverage that lured many seniors into HMOs in the first place. A four-year study of quality of care by John Ware, published in the October 2, 1996 issue of the Journal of the American Medical Association, found that seniors were more likely to decline in health under HMO care than in the traditional Medicare program. Yet instead of recognizing the failures of Medicare privatization, the Heritage Foundation and its allies in Congress push on.

While traditional Medicaid is a program of uneven quality, with large variations by state, the record of for-profit HMOs in treating Medicaid patients has clearly been worse. Florida officials banned 21 of the state's 29 Medicaid HMOs from expanding enrollment several years ago after systematic abuse of patients was uncovered not by state auditors but by courageous investigative reporters at a local newspaper. These HMOs used fraudulent marketing tactics (for instance, telling patients they would lose their Medicaid if they didn't enroll), delivered poor-quality care, disenrolled sick patients, and spent up to 70 percent of program costs on overhead and profits.

In Oregon, the percentage of poor women with inadequate prenatal care and the percentage of low-birthweight babies rose after Medicaid recipients were pushed into HMOs. A large experiment in which families were randomly assigned to HMOs found that low-income persons fared particularly poorly in the HMO setting.

A national health care system is financially viable. According to studies by both the GAO and the Congressional Budget Office, a single payer national health program would streamline health care paperwork and, in doing so, save enough money to cover the 44.3 million uninsured. It would allow patients to choose their own physicians and hospitals, a right citizens of most industrialized countries take for granted.

Drug companies have the highest rate of profit of any industry, and the United States has the highest drug prices in the world. According to a study by Alan Sager and Deborah Socolar at Boston University, if the U.S. government used its bargaining clout to negotiate drug prices down to Canadian levels, the savings (about $16.2 billion) would be sufficient to provide the 70 million Americans lacking drug coverage with necessary medications.

A recent New York Times article noted that the economy of Sweden is doing so well that the government is giving seniors the right to have a personal home care assistant. But when the U.S. economy does well, as it has since 1992, another 7 million people are thrown into the ranks of the uninsured.

No nation has ever achieved universal health care through the market. We and the 8,500 doctors at Physicians for a National Health Program believe that health care should not be a business but a human service that should be delivered through nonprofit national health insurance. The United States spends nearly twice as much on health care as any other industrialized country, including Sweden, and yet is the only one of these countries that does not guarantee universal coverage.

An editorial in the Bangor Daily News recently argued that "health care should be regarded as an essential part of an enlightened society" and that "health care ought to be viewed as a right of citizenship and not an obligation of business." Instead of tinkering with tax credits and HMOs, the candidates should be debating more fundamental questions.

Bill Bradley and Al Gore are pushing the corporate health agenda under the cover of liberal rhetoric. That's no way to get progressives' support.

Dr. Ida Hellander is Executive Director of Physicians for a National Health Program, based in Chicago. Dr. Steffie Woolhandler is Associate Professor of Medicine at Harvard and Co-Founder of Physicians for a National Health Program.
For-Profit Kidney Dialysis Centers Compromise Kidney Care

Treatment of end-stage renal disease (ESRD) is a big business in the United States—a $15.6 billion industry, according to the U.S. Renal Data System. More than 200,000 patients undergo dialysis every year, 68 percent of them receiving their treatment in free-standing centers operated for profit and there is concern that imperatives resulting from the profit motive may be compromising care. Medicare reimbursement for dialysis has remained flat since 1973, which may drive for-profit providers to maintain income by cutting corners on treatment. And because long term dialysis represents a relatively constant source of income, whereas transplantation does not, for-profit providers have an incentive not to refer patients for transplantation surgery, despite the benefits a transplant offers the patient.

A study published in the November 25, 1999, New England Journal of Medicine provides evidence that these concerns are justified. Researchers at Johns Hopkins and Harvard looked at differences in care between for-profit and not-for-profit facilities. They found that patients at for-profit facilities were 26 percent less likely to be placed on a waiting list for transplantation. Of even greater concern, they found that death rates were 20 percent higher among patients treated in for-profit facilities than among those treated in non-profits. To make the comparisons valid, the study population was adjusted for sociodemographic, clinical and other differences.

The authors wrote that “our results arouse concern about the current system of payment...that...does not provide incentives to maximize clinical outcomes.” They suggested that enhanced oversight or a new incentive system may be required to improve patient care, and noted that outcomes were improved in for-profit facilities when those facilities were located near competing not-for-profit facilities.

Another study published in the same New England Journal issue, by John Z. Ayanian, MD, MPP, et al. looked at apparent racial iniquities in transplantation. The researchers found that black ESRD patients were less likely to want transplants than white patients, and also less likely to be “very certain” about their decision not to pursue transplantation. However, after adjusting for the preferences and expectations, the data still showed large differences between blacks and whites in rates of referral for transplantation evaluations and in rates of placement on transplantation waiting lists within 18 months after beginning dialysis therapy. The differences also persisted after adjusting data for other variables including health status, type of dialysis facility, coexisting illnesses, socio-demographic characteristics and the cause of renal failure.

Ayanian et al. concluded that racial differences in preferences and expectations “explain only a small fraction of the substantial racial differences in access to transplantation.” Instead, the researchers suggested that “although few patients reported recent discrimination on the basis of their race, income, or sex...blacks may be more likely than whites to encounter problems in communicating with their physicians and may have less trust in the health care system.” The researchers recommended a number of ways to address the problems: 1) provide more systematic education about transplantation; 2) offer stronger encouragement to undergo transplantation and to consider potential living donors; and 3) monitor and inform doctors and medical groups about racial differences in referral rates among their own patients.

This latter research affirms the findings of a separate study published in the October 1, 1998 Journal of the American Medical Association, and reported in the November 1998 Health Letter. The earlier study indicated that blacks, women, and the poor are less likely to receive kidney transplants than other Americans with similar transplantation needs. At each of the four stages of the transplantation process (being declared medically suitable, being willing to receive a transplant, undergoing a pre-transplantation workup, and actually receiving a replacement kidney) these groups were disadvantaged by less care. The genuine life-saving benefit of kidney transplants has been confirmed in new research published in the December 2, 1999, New England Journal of Medicine. More than simply reducing medical expenses and improving quality of life, the procedure appears to extend the lives of patients suffering from ESRD. This makes comprehensive, equitable treatment for the disease imperative.

An accompanying editorial put findings of the new research in broader perspective. Its author, Norman G. Levinsky, MD, of the Boston University Medical Center, wrote that “the increased mortality among patients treated at for-profit facilities...and the lower quality of care in such facilities, reported by other investigators, suggest that, faced with the same financial pressures, for-profit facilities respond differently from not-for-profit facilities—to the detriment of patient care.” Levinsky remarked that the documented racial disparities are “part of a general pattern in the United States, in which blacks have less access than whites to numerous effective clinical treatments...Such differences...are especially unconscionable in a program [the Medicare End Stage Renal Disease Program] paid for largely by the U.S. Government.”

Levinsky suggested that further research is needed to identify ways to overcome inequities in the ESRD Program, to determine whether inadequate Medicare reimbursement rates have led to erosion of care quality, and to review the practices of for-profit facilities and the kidney specialists treating patients with ESRD.
Point/Counterpoint

Is It Ethical to Pay Research Subjects Large Sums?

The following debate is reprinted from the November 15, 1999 issue of Physicians Weekly© with permission of American Passage Media.

No
Christine Grady, R.N., Ph.D.
Department of Clinical Bioethics
National Institutes of Health

Several moral concerns support limits on the amount of money that should be offered subjects.

One is “undue inducement,” meaning that money may potentially cloud the judgment of individuals considering participation in research. As a result, several things could happen, all of which are negative.

People might gloss over, misunderstand, or miscalculate the potential risks and benefits of participating in a study.

A large sum might influence individuals to hide information about their medical history. This jeopardizes not only their own safety but also the integrity of the data and risks the safety of future patients.

A large payment might induce people to participate in a study even if they really don’t want to do so.

Large payments might also preferentially attract poorer subjects. The equitable distribution of the benefits and burdens of research is very important. We must ensure that certain groups or individuals are not asked to bear a disproportionate share of the burden. If money skews research participation toward the economically disadvantaged, the distribution of the burden would also be skewed.

Finally, many people are uncomfortable with the idea that someone might participate in research just for the money. Many feel strongly that the true nature of ethical research requires a person to at least understand that participating in research will benefit society.

Large amounts of money may obscure any consideration of other motives. People may not even begin to consider the altruistic aspects of being a research subject or understand the nature of the risks and benefits of the particular study in which they are enrolling.

Yes
Saul Levmore, J.D., Ph.D
William B. Graham Professor of Law
The University of Chicago School of Law

We already allow the payments—the question is how high these payments should go.

Often, inconvenience and lost time, not risk, are recruitment barriers. Paying a few thousand dollars—if that’s what it takes—to people who must endure confinement or side effects is better described as meeting a market clearing price, not unethical behavior.

The ethical rules in place remind researchers to take subjects’ and society’s needs into account. In many studies, researchers’ interests are already well aligned with those of patients. If researchers overpay, potential subjects may withhold medical information to avoid exclusion from the study.

But scientists lose out if subjects suffer because of undisclosed factors in their medical histories. Research could be ruined. Therefore even the most selfish researcher has an incentive not to overpay.

The ideal of highly paid doctors, scientists, politicians, and hospital administrators declaring what is fair reimbursement can be offensively paternalistic. In fact, some subjects receive only the minimal payments that are currently deemed ethical for months of experiments. If we paid more attention to these people’s sentiments, there might be a call to increase payments. Perhaps it should be unethical to underpay.

Existing rules about payments to human subjects are vague. The current conventions stem in part from uncertainty about what others will see as ethical and even legal.

There was once a convention of restrained payments to egg donors. But market forces shattered this, perhaps because those who seek fertility treatment are often affluent and politically astute. Payment norms in other areas of medicine may also change, especially if we talk openly about the issue.
The recalls noted here reflect actions taken by a firm to remove a product from the market. Recalls may be conducted on a firm's own initiative, by FDA request, or by FDA order under statutory authority. A Class I recall is a situation in which there is a reasonable probability that the use of or exposure to the product will cause serious adverse health consequences or death. Class II recalls may cause temporary or medically reversible adverse health consequences. A Class III situation is not likely to cause adverse health effects. If you have any of the drugs noted here, label them Do Not Use and put them in a secure place until you can return them to the place of purchase for a full refund. You can also contact the manufacturer.

If you want to report an adverse drug reaction to the FDA, call (800) FDA-1088. The FDA website is http://www.fda.gov.

Our listing of drug recalls this month includes Class I recalls of almost 2 million kits and injections for treating allergic reactions. The epinephrine in these injections and bee-sting allergy kits was found to be subpotent. This could pose a potential health hazard for those with known allergies because the epinephrine increases blood flow and could cause serious adverse consequences or death could result from this defective product. All of these products were manufactured by Wyeth-Ayerst Laboratories, a division of American Home Products. The recall includes:

- **a) Ana-Kit Anaphylaxis Emergency Treatment Kit**—consisting of one syringe (1.0 mL) containing two single doses (0.3 mL) of Epinephrine Injection USP, (1:1000) labeled in part Pkgd. and Dist. By: Bayer Corporation Pharmaceutical Division, Spokane, WA 99207, sold as individual kits or 6-packs. NDC 0026-9988-01 and 0026-9988-06

- **b) Ana-Guard Epinephrine Injection USP (1:1000)**—consisting of one syringe (1.0 mL) containing two single doses (0.3 mL) of Epinephrine Injection USP, (1:1000), labeled in part ANA-GUARD EPINEPHRINE INJECTION, USP (1:1000) ** Pkgd. and Dist. By: Bayer Corporation Pharmaceutical Division, Spokane, WA 99207 NDC 0026-9984-01 and 0026-9984-06

- **c) Epinephrine Injection, USP (1:1,000) Syringe**—a refill item for the above two sold as 500 syringes/box under NDC# 0026-9982-01 each containing two single doses (0.3 mL) of Epinephrine Injection USP, (1:1000)

- **d) DERM/BURO INSECT STING KIT, Rx**—consisting of one syringe (1.0 mL) containing two single doses (0.3 mL) of Epinephrine Injection USP, (1:1000), Pkgd. and Dist. by: Derm/Buro Inc., Deerfield, IL 60015

- **e) Epinephrine Injection, USP, 1:1000, Rx, in 1 mg/1 mL Tubex syringes, (25 gauge 5/8 inch needle) units of 10**

All kits and syringes should be returned to the hospital, clinic or pharmacy where they were obtained. If you have any questions about the lot numbers and exact kits that are subject to this recall, check with your pharmacy. You can also find this information on the FDA website at http://www.fda.gov/bbs/topics/ENFORCE/ENF00617.html

<table>
<thead>
<tr>
<th>Name of Drug or Supplement</th>
<th>Class of Recall</th>
<th>Problem</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Albuterol</strong>—Warrick Pharmaceuticals brand, Inhalation Aerosol, 17 g, 200 metered inhalations, Rx for prevention and relief of bronchospasm; Class III; Insert mislabeling; insert incorrectly instructs user to only use with orange mouth piece, while product is accompanied by white mouthpiece, the correct color</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aldoril D50 Tablets</strong> (Methyldopa (500mg)-Hydrochlorothiazide (50mg)), in 100 tablet bottles, Rx used to control hypertension; Class III; Dissolution failure for Hydrochlorothiazide</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anzemet Tablets</strong> (Dolasetron Mesylate), 100 mg, bottles of 5 tablets, Rx anti-nauseant and anti-emetic; Class III; Stability (6 month) test failure elevated degradation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lot #: Quantity and Distribution: Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot Numbers: B5511 EXP 1/00, D5714 EXP 4/00, D5719 EXP 4/00, E6156 EXP 4/00, E6172 EXP 2/00, H3896 EXP 4/00; 15,424 bottles distributed nationwide; Merck and Company, Inc., West Point, Pennsylvania</td>
</tr>
<tr>
<td>Lot Numbers: 3001616 EXP 2/01, 3003145 EXP 2/01, and 3003148 EXP 4/01; 10,329 bottles distributed in Ohio and Missouri; Hoechst Marion Roussel, Inc., Cincinnati, Ohio</td>
</tr>
</tbody>
</table>

Public Citizen's Health Research Group ♦ Health Letter ♦ 5
## DRUGS & DIETARY SUPPLEMENTS, cont.

<table>
<thead>
<tr>
<th>Name of Drug or Supplement; Class of Recall; Problem</th>
<th>Lot #: Quantity and Distribution; Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Country Health Formula #63 MSM Eye and Ear Drops</strong>, OTC, in 1 ounce bottles; Class II; Current good manufacturing practice deviations</td>
<td>Lot Numbers: 433, 7538, 9463 and 9749; 541 containers distributed in Idaho; Cosmetic Specialty Labs, Inc., Lawton, Oklahoma. Recalled by BioMechanics, Aberdeen, Idaho</td>
</tr>
<tr>
<td><strong>Derma-Clear(tm), Skin Bleaching Treatment and Jeval A-Peel,</strong> Skin Bleaching Treatment, over-the-counter topical cream in 2 and 4 oz. plastic jars, (same ingredients, 2 trade names); Class II; New drug without new drug approval (contains more than 2% hydroquinone)</td>
<td>Lot &amp; (Batch) Numbers: 90-0-5 (3728), 0-0-5 (3728), 1234567890-7 (4314), 234567890-7 (5109), 34567890-7 (5245), 4567890-7 (5461), 567890-7 (6197), 67890-7 (6242), 7890-7 (7237); 5,279 units distributed in Texas; Cosmetic Specialty Labs, Inc. (CSL), Lawton, Oklahoma</td>
</tr>
<tr>
<td><strong>Duratuss G Tablets,</strong> (Guaifensin), 1200 mg, in 500 tablet bottles, Rx 12-hour sustained release expectorant; Class III; Dissolution failure</td>
<td>Lot Numbers: J980726A and J980727A; unknown quantity distributed in Wisconsin; Mikart, Inc., Atlanta, Georgia</td>
</tr>
<tr>
<td><strong>Hibistat Germicidal Hand Rinse,</strong> (Chlorhexidine gluconate), 0.5% w/ w, OTC, used by health care professionals as a germicidal hand rinse; Class III; Alcohol low potency and specific gravity failure; rework without current good manufacturing practice control</td>
<td>Lot #3152B EXP 4/01; 33,432 bottles distributed nationwide and in Saudi Arabia; Accupac, Inc., Mainland, Pennsylvania. Recalled by AstraZeneca, Wilmington, Delaware</td>
</tr>
<tr>
<td><strong>Invigorate(tm) Liquid Drink</strong> in 32 fluid ounce plastic bottles. Label declares as an ingredient 2(3H) Furanone Di-hydro, also known as gammabutyrolactone (GBL), a supplement which stimulates the body's own ion of human growth hormone and as a supplement which <em>will induce deep invigorating sleep that will last 3-4 hours;</em> Class I; Unapproved new drug</td>
<td>All lots remaining on the market; Undetermined quantity distributed nationwide; Invigorate International, New York, New York. Recalled by Cabot Industries, LLC, West Babylon, New York</td>
</tr>
<tr>
<td><strong>Klonopin (brand of Clonazepam) Tablets,</strong> 0.5 mg, 1 mg, and 2 mg, distributed in bottles of 25 and 100 tablets; Class III; Impurity level exceeds specification</td>
<td>All lots, NDC 0004-0068-01, 0004-0068-50, 0004-0058-01, 0004-0058-50, 0004-0098-01 and 0004-0098-50; Approximately 48,706 bottles distributed nationwide; Roche Pharma, Inc., Humacao, Puerto Rico. Recalled by Roche Laboratories, Inc., Nutley, New Jersey</td>
</tr>
<tr>
<td><strong>Koleprin DM Caplets,</strong> in 30 caplet bottles, OTC prompt release, cough and cold medication; Class III; Friability failure</td>
<td>Lot #98603 EXP 2/01; 2,659 units distributed nationwide; SSS/Pfeiffer Pharmaceuticals, Inc., Atlanta, Georgia</td>
</tr>
<tr>
<td><strong>Requlp</strong> (Ropinirole Hydrochloride) 1 mg tablets, In bottles of 100, Rx for the treatment of Parkinson's disease; Class III; Tablets have been found to fade from green to yellow, making it difficult to distinguish between strengths or could cause the wrong product to be dispensed</td>
<td>Numerous lot numbers; 20,000 bottles distributed nationwide; SmithKline Beecham Pharmaceuticals, Crawley, West Sussex. Recalled by SmithKline Beecham Pharmaceuticals, Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td><strong>Recaltrol Capsules,</strong> (Calcitriol), 0.25 mcg, Rx, in 100 capsule bottles; Class II; Potential microbial contamination (Bacillus cereus/ Methylobacterium sp)</td>
<td>Lot #0419 EXP 10/31/00; 173 bottles distributed nationwide; Roche Laboratories, Inc., Nutley, New Jersey</td>
</tr>
</tbody>
</table>

## MEDICAL DEVICES

Device recalls are classified in a manner similar to drugs, Class I, II or III, depending on the seriousness of the risk presented by leaving the device on the market. Contact the company for more details. You can also call the FDA's Device Recall and Notification Office at (301) 443-4190. To report a problem with a device, call 1-800-FDA-1088. The FDA website is http://www.fda.gov.

<table>
<thead>
<tr>
<th>Name of Device; Class of Recall; Problem</th>
<th>Lot #: Quantity and Distribution; Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proclear Compatibles Daily Wear Contact Lens; Class II;</strong> Leaking blister seal of contact lens packaging compromised sterility</td>
<td>416 lots of lenses each identified with a 10 digit reference number; 119,028 lenses distributed nationwide; Biocompatibles Eyecare, Inc., Norfolk, Virginia</td>
</tr>
</tbody>
</table>

6 * January 2000
Contact the Consumer Product Safety Commission (CPSC) for specific instructions or return the item to the place of purchase for a refund. For additional information from the Consumer Product Safety Commission (CPSC), call their hotline at 1-800-638-2772. The CPSC website is http://www.cpsc.gov.

<table>
<thead>
<tr>
<th>Name of Product: Problem</th>
<th>Lot #: Quantity and Distribution: Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aquarium Lights:</strong> Sharp edges on lights could cut insulation on the wiring. If wires become exposed, can cause shocks, electrocution and fire risk</td>
<td>All 36-inch SHOiights that hold two bulbs, and all SHOiights lights manufactured in July 1999 or earlier; 23,400 sold nationwide from August 1998 through July 1999; Perfecto Manufacturing Inc., Noblesville, Indiana (800) 241-7485</td>
</tr>
<tr>
<td><strong>Boys Jackets:</strong> 7-inch drawstrings at the bottom of the jackets. Children could be dragged if the drawstrings catch in a vehicle's door, and suffer injury or death</td>
<td>USA Olympic brand; 20,000 J.C. Penney Co., Inc., Plano, Texas (888) 333-6063 <a href="http://www.jcp.com">www.jcp.com</a></td>
</tr>
<tr>
<td><strong>Bunk Beds:</strong> Top bunk does not have guardrails on both sides. A child could fall or become entrapped between the wall and the mattress</td>
<td>Sold under the model names Prestige, Spindle, and Cottage, made of Northern White Ash with natural, cherry, honey or golden finishes; 2,800 sold at furniture and specialty bedroom stores throughout New England from May 1995 through February 1998; Northern Bedding's Inc., Oxford, Maine (888) 800-7708</td>
</tr>
<tr>
<td><strong>Camp Mess Kits:</strong> Sauce pan handle does not lock into place and fry pan handle can bend during use, spilling hot foods or liquids onto consumers and causing serious burns</td>
<td>Texsport label, 5-Piece kit; 146,000 sold at camping, mass merchandising and army surplus stores nationwide and in Puerto Rico from May 1994 through September 1999; Southern Exchange Co. Inc., Houston, Texas (800) 231-1422</td>
</tr>
<tr>
<td><strong>Children's Pajamas:</strong> The pajama sets fail to meet federal children's sleepwear flammability standards</td>
<td>Style numbers 353558, 353554, 733002, 733032, 466291 and 67060. The style numbers are located on labels sewn into the side seams or collar of the garment; 231,000 sold at GapKids, babyGap, Gap Outlet and Old Navy stores nationwide from August through December 1999; Gap Inc., San Francisco, California (800) GAPSTYLE or (800) OLD NAVY <a href="http://www.gap.com">www.gap.com</a> or <a href="http://www.oldnavy.com">www.oldnavy.com</a></td>
</tr>
<tr>
<td><strong>Electrical Voltage and Continuity Testers:</strong> Batteries in tester could fail to maintain proper contact due to corrosion within the battery compartment, causing device to lose power posing risk of shock, electrocution, and thermal burns</td>
<td>Model T-2 hand-held with serial number lower than 74155430; 58,000 sold nationwide from December 1997 through September 1999; Fluke Corp., Everett, Washington (800) 753-8646 <a href="http://www.fluke.com/whatsnew/Notices/notices_99-10-01.asp">www.fluke.com/whatsnew/Notices/notices_99-10-01.asp</a></td>
</tr>
<tr>
<td><strong>Mountain Bikes:</strong> Defective handle bar stems which do not tighten sufficiently to lock onto bicycles which can cause front wheel not to turn properly, resulting in serious injuries to the rider from falls</td>
<td>Magna &quot;Great Divide,&quot; 21-speed mountain bikes (24-inch size for girls and boys, 26-inch size for women and men). The words &quot;Great Divide&quot; are located on the cross-tubes of these bicycles and the word &quot;KALLOY&quot; is located on the handlebar stems; 3,000 sold at Fred Meyer Stores in Alaska, Arizona, Idaho, Oregon, Utah and Washington from December 1998 through August 19, 1999; Dynacraft Industries Inc., San Rafael, California (800) 551-0032</td>
</tr>
<tr>
<td><strong>Sewing Machines:</strong> When removing the sewing machines power cord from the power transformer on the sewing machine, loose pins from the power transformer could remain in the cord, posing a risk of electric shock</td>
<td>Husqvarna Viking model #1+ Serial Number Range between 10000001 and 19999991, Serial Number Range between 20000000 and 29999999, Serial Number Range between 33600003 and 33699993, Serial Number Range between 50000002 and 59999992; 1,100 sold nationwide from January 1998 through September 1998; Viking Sewing Machines Inc., Cleveland, Ohio (800) 446-2333</td>
</tr>
<tr>
<td><strong>Trampoline Safety Net Enclosures:</strong> Straps on the bottom of the net can break. Children can fall out under the net and off the trampoline and be injured</td>
<td>Look for black buckles and black or red extension straps on the yellow straps; 2,300 sold at Costco, BJs, Academy and Bradlees stores nationwide from February to July 1999 for about $150 to $230; JumpSportInc., of Saratoga, California (888) 567-5867</td>
</tr>
<tr>
<td><strong>Underwater Strobes:</strong> If strobe becomes flooded, gas build-up can cause battery cap to forcefully eject off of the strobe or cause front section to violently separate from the back section</td>
<td>Models YS-50, YS-60 and YS-120 with serial numbers beginning with 96 or 94; 7,000 sold nationwide from February 1998 through March 1999; Sea &amp; Sea Underwater Photography (U.S.A.) Inc., Carlsbad, California (800) 732-7977</td>
</tr>
</tbody>
</table>
Health Letter Volume Index, 1999

Volume 15, Number 1, January 1999
- FDA Medical Officers Report
- Lower Standards Permit Dangerous Drug Approvals
- Healthy Patients and Wealthy HMO Stockholders: An Impossible Mix
- Product Recalls
- Health Letter Volume Index, 1997 and 1998
- Health Letter Cumulative Alphabetical Index
- Outrage: Andy Rooney: The Tobacco Deal

Volume 15, Number 2, February 1999
- "Going Bare": Uninsured Portion of U.S. Population Is Growing Rapidly, Survey Discloses
- The Drug Approval Process
- Product Recalls
- A Dirty Little Secret: Managed Care is Bad for Business
- Outrage: One More Hoax: The Neediest Would Get No Benefit from Clinton's Proposed Tax Credit

Volume 15, Number 3, March 1999
- The New Edition of Worst Pills, Best Pills
- Serious Health Insurance Problems
- Exhaustion that Kills: Why Residents are Still Overworked—and What We Can Do About It
- Product Recalls
- Outrage: The FDA and Abbott Are Comfortable—Would You Be?

Volume 15, Number 4, April 1999
- Adverse Drug Reactions
- Crazy About Sex [Problems]
- Preventing Osteoporosis, Falls and Fractures in Older Adults
- Medicare Must Cover Prescription Drugs and Control Prices
- The ACLU’s Tobacco Addiction, Continued
- Product Recalls
- Outrage: Lessons from the George Lundberg Firing

Volume 15, Number 5, May 1999
- Public Citizen's Health Research Group Ranking of State Medical Board Disciplinary Actions in 1998
- International Research Ethics Codes Under Siege
- Notes from Sidney Wolfe's Mom Nurses, Patients and Managed Care
- Product Recalls
- Outrage: The Troglitazone (REZULIN) Safety Meeting

Volume 15, Number 6, June 1999
- Public Citizen’s Health Research Group Petitions the FDA to Revise Labeling on the Breast Cancer Drug Tamoxifen (NOLVADEX)
- In the Public Interest
- In Memoriam: John O. Nestor, M.D.
- Product Recalls
- Dangerous Drug Information on the Internet from Aetna/U.S. Healthcare and Johns Hopkins
- Outrage: Prescription Drug Profiles—Accessible to All?

Volume 15, Number 7, July 1999
- Preventing Heat-Induced Death and Illness
- The Wild, Wild Web
- Safety of Speedy FDA Drug Approval Being Questioned
- Asleep on the Job
- Product Recalls
- Workplace Deaths: Where is the Federal Prosecution of Employers?
- Outrage: Star Wars and Drugs

Volume 15, Number 8, August 1999
- Below the Beltway: K Street Gore Second Opinion: Temptation Makes a House Call
- Product Recalls
- Health Talk: Doctors Online
- Worse Quality Medical Care in For-Profit HMOs Than in Not-for-Profits
- Outrage: Dr. Koop: Part I

Volume 15, Number 9, September 1999
- Hidden Rip-off in U.S. Health Care is Unmasked in New England Journal of Medicine Articles
- Fraudulent Health Claims: Don't Be Fooled
- Product Recalls
- Off-Label Dangers
- Young Children Continue to Die Unnecessarily on U.S. Farms
- Outrage: Pfizer Caught Trying to Subvert National Guidelines for Treating Children's Ear Infections

Volume 15, Number 10, October 1999
- Clinton Administration Scuttles Worker Protections
- An Interview with Breastfeeding Advocate and Formula Fighter Bobbi Philipp, M.D.
- "Try It, You'll Like It"—For a Hefty Price: The Drugmakers' Scam on the Public
- When Money is the Mission—The High Costs of Investor-Owned Care
- Product Recalls
- Outrage: Doctors and Rexall Combine to Push Worthless Dietary Supplements to Patients

Volume 15, Number 11, November 1999
- Losing Weight: The Truth is Hard to Swallow
- Product Recalls
- Another Medical Myth Laid to Rest
- Outrage: Bradley and Gore Rehash Stale Ideas

Volume 15, Number 12, December 1999
- 'Hope Lodge' Movement Offers Hope to Cancer Patients Away from Home
- Medical Merger
- Product Recalls
- The Grass Really is Greener to the North
- Important Safety Reminder—Reye's Syndrome and Aspirin
- Some More Questions About Your HMOs
- The Science of Arresting Human Intelligence Long Enough to Get Money from It
- Outrage: Milton, Matthew and Managed Care
Health Letter Cumulative Alphabetical Index (through 12/99)

Topics are listed alphabetically. Following each topic, the volume and issue number of the Health Letter containing the article is listed. For example, an article on the topic of Accutane can be found in volume 4 number 5 (V4#5) of the Health Letter. Volumes are chronological (volume 1 was issued in 1985). Back issues are $1.50 each. Indicate issues wanted and send check made to Public Citizen, 1600 20th Street, NW, Washington, DC 20009.

A

AARP: V5#6, V5#7, V7#6, V7#8, V8#1, V8#3, V8#4, V8#8, V9#2, V9#5, V9#12, V10#2, V10#9

Abbokinase: V15#3

Accutane: V4#5, V4#6, V5#6, V6#7

ACE Inhibitors: see Hypertension

Acetaminophen: V7#3, V10#12 (with alcohol), V11#2

ACLU: V9#9, V10#1, V14#12, V15#4

Advance Directives: V7#11

Adverse Drug Reactions: V6#4, V6#11, V9#10, V15#3, V15#4

Advertising: see Drug, Advertising Reporting: V8#10, V9#7, V12#3, V14#5, V14#6, see also Food and Drug Administration

AETNA: V15#6

Affirmative Action: V13#4 (doctors)

AIDS: V1#5, V3#8, V4#2

Commission: V3#11

Drug Price Control: V4#10

HIV/Unethical Experiments: V13#6, V14#5

Home Test Kits: V13#11

Knowledge: V7#7, V8#1

Needle Exchange Programs: V12#3, V12#4

Unapproved Drugs: V4#9

Vaccine Studies (army): V10#12

Air Force, Drug Use: V4#9

Air Traffic Controllers: V3#12

Alar: V2#3, V2#4, V3#6, V3#9, V4#4, V5#7

Albuterol: V10#2

Alev: V10#8

Allergies: V1#6, V6#12

Alprazolam: see Xanax

Alternative Medicine: V2#11

Alupent: V10#5

American Cancer Society: V14#5

American Cancer Council on Science & Health: V5#5

American Heart Association: V14#5

American Medical Association: V4#4, V5#6, V5#11, V6#2, V7#10, V10#1, V10#2, V10#9, V11#6, V13#4, V14#3, V14#5, V15#4

Amoxicillin: V15#9, correction V15#11

Angioplasty Catheters: V9#12

Antibiotics: V5#7, V11#8, V13#10

Anticoagulants: V9#9

Anti-Aging Hormones: V14#2

Anti-Diarrhea Drugs: V9#2

Antidepressants: V11#2

Cost Comparison: V14#9

Antihistamines: V8#9

Antipsychotics: V14#9 (cost comparison)

Apnea Monitors: V9#10

Arthritis: see Feldene

Arthritis Foundation: V10#12

Artificial Nail Glue: V6#11

Asbestos: V4#8, V5#8

Aspirin

Atrial fibrillation: V6#5

Heart attack/stroke: V2#1, V4#9, 5#9, V7#9

Reye's Syndrome: V1#1, V1#2, V1#5, V1#6, V2#2, V3#5, V5#10, V9#7, V15#12

Asenzimole: see Hismanal

Asthma: V1#6, V6#12, V10#2, V10#3 and Women: V7#3

Ativan: V1#4, V3#4

Autologous Blood: V3#4

Awards: V9#3, V11#5, V12#5, see also Project Censored

Azithromycin: See Zithromax

Bromocriptine: V4#7, V5#1, V5#7, V9#10, V10#10

Bucks, Danger to Children: V6#10

Budget Bill: V13#10

Bupropion: see Wellbutrin

Burt, Dr. James: V4#12

Buspar (buspirone): V3#12, V4#4

Bypass Surgery: see Coronary Bypass Surgery

C

Cadmium: V3#3, V3#8

Calcium: V3#6, V14#2

Cancer: see type of cancer

Business: V7#3

Causing Chemicals: V4#1, V7#2

Causing Pain Relievers: V7#3

Delaney Clause: V3#12, V8#10

Capoten (captopril): V5#10

Carbon Monoxide and Heart Disease: V6#12

Care of the Seriously Mentally Ill: V2#2, V4#11, V6#10

Carpet Hazards: V5#3

Catastrophic Coverage: see Medicare

Cellular Phones: V12#7, see also Pacemakers

Centrax: V1#4, V3#4

Cesarean Sections, Unnecessary: V3#11, V3#12, V4#1, V5#3, V8#6, V10#6

Cesarean Sections, Rates: V7#6, V7#9

Doctor Defamation Suit: V14#4

Chemical Burns: V8#4

Chemical-caused Sterility: V13#12

Chemical Hazards: V1#5, V13#12

Chemical Industry: V1#1

Chemicals in Carpets: V3#3

Chickenpox: V11#8

Childbirth: see Cesarean Sections; Midwives

Children, poisoned: V13#12

Child-Proof Medication Containers: V6#5

Chiropractic Treatment: V14#11

Chlorazepate: see Tranxene

Chlordiazepoxide: see Librium

Cholestrol: V4#8, V5#12, V10#12

Cholesterol-lowering Drugs: V10#12

Cholestyramine: V4#9

Chromium: V3#9

Chronic Fatigue Syndrome: V4#4

Public Citizen's Health Research Group    Health Letter    9
Cigarettes: see Tobacco
Cisapride: see Propulsid
Claritin: see Vizmatazine
Clozoxapine: see Cogex
Coffee, Decaffeination: see Methylene Chloride
Cognex: V10#1
Colds: V9#1, V9#2
Color Additives: see Food Dyes

Commerce Department Health Cost Statistics: V8#2, V9#2, V10#2
Community Right to Know: see Right to Know
Constipation: V3#4, V3#7
Consumer Product Safety Alert: see Product Safety Alert
Contact Lenses: see also X-rays

Coronary Artery Disease: see Heart Disease
Cornstarch
Crohn's Disease: see Inflammatory Bowel Disease

Dalmane: V1#4, V3#4
Dalamizole: see Alar
Danthorn: V3#4, V3#7
Darvon: V5#8
Decaffeination: see Methylene Chloride
Defibrillators: V9#10
Delaney Clause: V3#12, V8#10, see also Cancer

Dental X-rays: see X-rays
Denture Adhesives: V7#3
Deprenyl: see Leprine
Depression: V5#4, V6#12
DES: V1#2, V1#3, V1#4
Devices: see Medical Devices

Dexedrine: V4#9, V4#10
Diabetes: V4#12, V13#2
Diarrhea: see Anti-Diarrhea Drugs
Diazepam: see Valium
Diclofenac: see Voltaren

Diethylthilbamol: see DES

Diet: V2#1
Clincs: V1#4
Pills: V7#1, V1#4
Products: V5#6, V13#11, V15#10

Doctor Bribing Hotline: V6#3, V8#5, V13#10
Competency Testing: V9#1
Corporate Deals: V12#2
Data Disclosure: V1#3, V5#11, V5#12, see also Naional Practitioner Data Bank

Diversity: V13#4
Fraud: V3#6
Incomes: V3#11, V5#1, V5#5, V6#7, V6#10, V8#6, V9#2, V9#3, 11#10, V13#2
Kickbacks: V5#5, V5#6, V5#7, V6#1, V9#13, V9#14, 10#10, 15#8, 15#10
Managed Care Opinions: V13#3, V13#4, V13#9, V13#11, V1#4
Patient Relationship: V11#4, V12#11, V1#4
Physician Profiles (Massachusetts): V12#12
Quality of Care: V4#8
Residents, Working Hours: V15#3, V15#7
Sanctions: V6#8, V7#7, V9#10, V9#11, V10#5, V10#8, V11#4, V12#4, V12#5, V12#12, V13#2, V13#5, V13#7, V14#3, V14#4, V15#8
Appeals from Sanction: V8#11
California Law Allowing Doctors to Have Sex With Patients: V8#11
Drug Enforcement Administration: see Drug Enforcement Administration
Medicare: see Medicare, Doctors Sanctioned
Ranking of States: V1#5, V3#2, V4#4, V5#11, V7#1, V9#3, V9#8, V10#6, V11#5, V12#5, V13#5, V14#5, V15#5
State Boards: V6#8, V7#7, V9#11, V12#4, V12#5, V12#12, V13#5, V14#3
State Initiatives: V7#1, V12#12
Self-referral: V7#10, V8#3, V8#4, V9#1, V9#5, V9#10
Selling Patients: V3#9
Sex-Related Offenses: V13#7
Training: V5#9, V9#1

Dorbutyn: see Danthron
Doxidin: see Danthron
DPT: V4#5

Drug - see also Over-the-Counter
Advertising: V1#4, V5#8, V8#8, V10#2, V10#12, V11#8, V11#9, V15#10, V12#3 (to medical students), V12#10 (to pharmacists), V12#12, V13#8, V14#2 (to consumers), V14#9 (USA Today), V14#10, V15#7, V15#10 (to consumers and physicians), V15#12 (company representatives)
Antidepressants: V11 #2
Approval: V2#5, V4#9, V5#10, (Council on Competitiveness Plan) V8#1, (moving too quickly), V14#8, V15#1, V15#2, V15#7
Exports: V3#1, V3#2, V8#12, V9#9
Generic: V5#8, V4#11, V6#10, V11#3, V13#9

Induced Diseases: V4#9, V5#8, V7#8, V8#1, V13#2, V13#6, V14#6
Industry: V15#12 (mergers)
Criminal Activity: V7#3
Detailpersons: V15#12
Gifts: V7#10, V13#8, V14#10

Labeling: V9#9 (Third World), V11#9, V11#11
Liability: V6#7
Off-Label Uses: V5#9
Older Adults Study: V10#9
Painkillers: V11#2
Perks: V5#5, V6#1, V13#8, V13#9
Policies: V15#6
Prescribing: V5#1, V5#2, V6#4, V8#3, V12#1, V13#6
Prescription Information: V12#1, V13#6, V14#8
Prescription Privacy Concerns: V14#4
Prescription to Over-the-Counter: V6#9
Prescription Profiles: V15#6
Prices: V6#3, V8#7, V9#13, V13#3 (compared with foreign countries), V14#9
Product Safety: V14#5
Recalls: V8#7, V8#10, V9#1, V9#4, V9#7, V9#10, V10#1, V10#4, V10#7, V10#10, V11#1, V11#4, V11#7, V11#10, V12#1, V12#4, V12#7, V12#10, V13#1, all issues beginning with V13#3
Research, Conflict of Interest: V9#11, V10#2, V13#9
Sales: V7#9 (Versed)
Third World: V8#12
Worksheet: V8#3

Drug Enforcement Administration, Doctor Sanctions: V4#3, V5#4, V6#4, V7#12, V12#4, V12#5
Dumping: see Patient Dumping
Duragesic Pain Patch: see Fentanyl
Dust Mites: V6#12
Dyes: see Food Dyes

Ear Infections: V15#9, correction
V15#11
Eldepryl: V11#2
Electromagnetic Fields: V10#8, V12#6
Elnensys: V14#4
Emergency Rooms: V7#12, V11#2, V11#7, see also Patient Dumping
Enalapril: see Vasoate
Enkaid (encaïneid): V5#7, V5#11
Enteroiioform: see Viomform
Environmental Hazards: V1#5, V9#3
Epilepsy: V2#1
Ergoloid Mesylates: see Hydergine
Esrstogen: see Birth Control Pills, DES, Hormones
Mepenozapal: V5#9, V7#6
Therapy: V3#6, V5#9, V13#6, V13#8, V14#2
Ethyl Hexadecil: V7#11

Exercise: V5#12
Osteoporosis: V4#5
Seniors: V7#8
Women & Diabetes: V8#8
Experimentation, Human: V3#10, V6#11, V7#2, V11#4, V12#11, V14#5, V14#7, see also Institutional Review Boards

E
Health Care

Hay

Haiti Children, poisoned: V13#12

Hay Fever: V16#6

Health Care System: V6#5, V8#11, V10#5, V10#10, V11#12, V12#3, V12#10, V13#4, V13#6, V13#11, V14#1, V14#3, V14#5, V14#8, V14#12, see also National Health Insurance

Canadian Doctor View: V10#1, V10#2

Comparison with Other Countries: V3#4, V4#5, V5#11, V5#12, V6#8, V7#6, V7#12, V8#8, V8#9, V9#6, V9#10, V14#4, V14#5

Corporate Health Care: V12#2, V12#4, V12#6, V12#9

Costs: V4#5, V4#8, V7#1, V7#2, V8#2, V9#2, V9#3, V10#2, V11#4, V12#3, V12#4, V12#10, V13#5, V15#9

Health Competition: V14#4

Managed Care: see Managed Care

Profits from: V12#2, V12#4, V12#8, V12#10, V12#12

Waste, Administrative: V4#8, V9#6

Health Detectives Handbook: V1#5

Health Insurance: see Insurance, Health

Health Maintenance Organization: see HMOs

Health Mergers: V10#7, V11#9, V12#6, V12#7, V12#9, V12#10, V13#1, V13#5, V15#5, V15#12

Health PACs: V5#6

Hearing Aids: V9#10, V9#12

Heart Disease: V5#12, V6#9

Carbon Monoxide: V6#12

High Blood Pressure: see Hypertension

High-Heeled Shoes: see Osteoarthritis

HIV

Experiments: V13#6, V14#5

Research Ethics: V15#5

Hismanal: V8#9, V9#7

HMO: V1#2, V6#1, V7#10, V7#11, V10#3, V10#12, V11#2, V11#4, V11#5, V11#6, V11#7, V12#2, V12#9, V12#11, V12#12, V13#1, V13#2, V13#3, V13#7, V13#9, V13#11, V13#12, V14#2, V14#7, V14#12, V15#1, V15#12 see also Medicare, Medicaid/HMOs

Mastectomy: V13#9

Arbitration Process: V13#9

Access: V12#9, V13#12, V14#2, V14#12

Comparisons: V14#7

Cost Consideration: V13#1, V14#2, V14#9

Discipline: V13#2, V13#5, V14#4

Doctor-run: V13#7

For-Profit vs. Not-For-Profit: V12#2, V13#3, V14#7, V14#9, V15#8

Mentally Ill Treatment: V13#3

Mergers: V13#1

Hoechst: V7#3

Hoffman-LaRoche: V7#9

Home-Testing Kits: V3#11

Hope Lodges: V15#12

Hormones: V14#2 (anti-aging), see also Estrogens

Hospices: V9#8

Hospitability, Unnecessary: V3#5

Hospitals

Buying MD Practices: V3#9

Buying Patients: V7#4

Conversions: V12#7, V12#10, V13#5

Costs: V10#4, V13#4

Disciplinary Actions: V13#2

Errors: V11#8, V13#2, V13#4, V14#8

For-Profit: V2#2, V7#7, V12#7, V12#9, V12#12, V13#4, V15#9, V15#10

Illegal Changing: V14#8

Incident Reporting: V5#10

Joint Commission on Accreditation of HealthCare Organizations (JCAHO): V6#1, V10#9, V10#10, V11#2, V12#7, V14#1

McDonalds in: V4#4, V4#10

Mergers: see Health Mergers

Mortality Data: V1#3

Acute Heart Disease: V4#2, V5#2, V6#5

Coronary Bypass Surgery: V2#2, V3#11

Negligence: V6#4

Not-for-Profit: V12#7, V12#12, V15#9

Nutrition: V4#4, V4#10, V6#9

Patients Rights: V7#4, V14#8

Quality of Care: V4#8, V4#9, V6#1

Self-Regulation: V13#2

Sick Hospitals (book overview): V8#2

Texas: V8#2 (border patrol)

Winstead, CT: V12#7

Human Radiation Exposure: V11#4

Hydrgine: V6#12

Hypertension: V4#9, V5#10, V6#3, V6#9

Hysterecomy: V6#2

I

Iatrogenic Disease: V4#9, V5#8, V6#7

Ibuprofen: V5#6, V6#6, V10#8

Ilosone: V5#10

Immunization, Chicken Pox: V11#8

Immunization, DPT: V4#5, see also

Taiwan Flu

Implants: V7#5, see also Silicone Gel Breast Implants

Incontinence: V8#2

Indexes:

Cumulative Alphabetic: 1985-1994: V11#1

Cumulative Alphabetic: 1985-1995: V12#1

Cumulative Alphabetic: 1993-1997: V13#1

Volume 1997 and 1998: V14#1

Volume 1996 and 1997: V14#1

Volume 1995 and 1996: V15#1

Volume 1994 and 1995: V12#1

Volume 1993 and 1994: V11#1

Inflammatory Bowel Disease: V10#9

Influenza: see Flu

Informed Consent: see Experimentation
Institutional Review Boards: V14#7, see also Experimentation, Human
Insulin: V13#2, V14#5
Insurance Companies: V6#12, V7#2, see also AARP
Insurance, Health: V311, V6#12, V15#3, see also National Health Insurance
Access: V14#5, V14#10, V14#12
Age Discrimination: V7#12
Blue Cross: see Blue Cross
Canadian System: V14#4, V15#12
Costs: V7#6, V11#7
Coverage: V14#3
Diabetes Coverage: V13#2
Employee Benefits: V12#8
Fraud: V11#4, V13#2
Golden Rule Company: V13#2
Long-Term Care, see Long-Term Care
Medical Bills Claims: V13#3, V13#7
Medical Savings Accounts: V12#10, V13#10
Medical Service Problems: V11#4
Medigap, see Medicare, Medigap
Mental Illness Payment: V12#11, V13#3
Michigan: V13#2
Pension: V13#3
Risk-Rated: V8#8, V11#6
State Health Plans: V6#11, V7#3, V8#7, V14#10
Unemployment, Epidemics of: V7#7, V8#6, V9#1, V11#2, V11#3, V14#11, V14#12, V15#2, Universal Coverage: V14#9, V14#12
Intraocular Lenses: V313
Iodinated Glycerol: V4#12, V9#6
Iodochlorhydroxyquin: see Viomycin
Irradiated Food: V2#1, V2#5, V3#6, V8#9
Isosorbide: V7#5
Internet: V13#9, V14#10 (health information), V15#6 (drug information), V15#7, V15#8
Ivermectin: V3#2

Kidney Transplant: V14#11
Koop: V15#8

L
Lab Testing: V3#10
Labeling: see Food
Labeling: V6#9
Lactation Suppressants: see Bromocriptine
Laparoscopy: V1#3
Laparoscopic Cholecystectomy: V8#8
Larium: V11#6
Lasix: V9#4
Latex Gloves: V14#2
Laxatives: V3#4, V3#7
Leaded Crystal: V7#5
Levamisole: V8#7
Liability (Drug & Device): V6#7
Librium: V1#4, V3#4
Lisinopril: see Prinivil
Listeria: V8#6
Liver Problems: V11#2
Living Will: V7#11
Lollipops: see Fentanyl
Long-Term Care Insurance: V6#5, V6#6, V6#8, V7#10, V7#12, V13#7, V13#12
National Program: V8#1, V8#7, V10#5, V15#2
Nursing Homes: V11#10
Plan FE (AARP): V9#12
Veterans: V7#11
Loratidine: see Claritin
Lorazepam: see Ativan
Lumpectomy: V6#2
Lundberg, George: V15#4
Lyme Disease: V3#7

M
Malpractice: V14#3, see also Doctor Sanctions
Malpractice Reforms (Bush): V7#7
Mammography: V7#8, V7#9, V11#1, V13#8
Managed Care: V10#3, V10#4, V10#12, V11#7, V11#9, V12#2, V12#7, V12#8, V12#11, V12#12, V13#1, V13#2, V13#3, V13#5, V13#9, V13#11, V14#2, V15#5, V15#12
Humor: V13#2, V13#6, V13#9, V13#11, V14#2, V15#5, V15#11
Managerial Medicine: V11#4
Manoplix: V9#7
Marijuana, Legalizing for Medical Treatment: V10#9
Massachusetts, Physician Profiles: V12#12
Mastectomy: V13#3
Methadone: see Methadone
Methamphetamine: V10#11
Medical Care: V11#6, V11#7
Medical Decision-making: V10#10
Medical Devices
Companies Liability: V6#7
Dangerous: V3#6, V5#5, V9#10, V9#12, V14#5
Effects of Metal Detectors On: V14#11
Recalls: V8#6, V8#9, V9#1, V9#3, V9#6, V9#9, V9#12, V10#3, V10#6, V10#9, V10#12, V11#3, V11#6, V11#9, V11#12, V12#3, V12#6, V12#9, V12#12, all issues beginning with V13#3
Regulation: V5#6, V5#10, V6#12, V8#5, V9#12
Reporting: see Food and Drug Administration, Adverse Drug Reporting
Medical Ethics: V10#3, V15#5
Medical Journals: V10#2
Medical Officers: see Food and Drug Administration
Medical Records Access: V2#4, V2#5, V3#1, V8#9, V11#9, V12#1
Medical Research, Funding: V7#3, V11#7, V12#6
Mental Health: V11#1
Medical Savings Accounts: V12#10, V13#2
Medical School, Letters From: V8#12, V9#4, V9#5, V10#2, V12#3, V12#5
Medical Students: V9#7 (drug industry perks)
Medicare:
Anti-fraud legislation: V12#8
Benefits: V9#9
Budget Cuts: V5#1, V6#12, V9#10, V11#5, V11#11, V11#12, V12#9, V13#10, V15#2
Catastrophic Coverage: V3#9, V4#3, V4#11, V5#5, V5#6, V5#7, V5#9, V5#11, V6#1, V11#12
Claims, Auto Phone System: V6#3
Congress: V11#4, V11#11, V11#12, V12#9
Costs, Out-of-Pocket: V1#2, V2#5, V3#11, V4#3, V8#4, V8#9, V13#10
Doctors Denied Payment: V4#7
Doctors Sanctioned: V3#5, V3#10, V3#12, V4#1, V4#7, V4#12, V7#2
Drug Prices: V6#3, V15#4
Educational Interventions: V7#11
Fraud: V12#8
HMOs: V11#5, V11#6, V11#12, V12#2, V12#11, V14#12
Home Health Benefits: V4#5, V8#6
Hospital Discharge (Early): V4#4
Hospital Mortality Data: see Hospitals, Mortality Data
Illegal Deposits: V8#10
Kidney Transplant Program: V14#11
Long-Term Care Insurance: see Long-Term Care Insurance
Malaise: V12#12
Mandatory Assignment: V3#9, V4#1, V5#7, V6#4, V8#4, V9#12
Medicaid: V11#12, V12#1, V13#10
Medigap: V5#7, V6#5, V6#8, V9#9, V12#3, V13#5

J
Jail Survey: see Mental Health
Jaw Implants: V7#6
Joint Commission on Accreditation of Health Care Organizations (JCAHO): see Hospital, Joint Commission on Accreditation of Health Care Organizations
Jim Bu Huan: V11#2
Johns Hopkins: V15#6, V15#7
Journalism Awards for Health Letter: V9#3, V11#4, V12#5

K
Ketoprofen: see Orudis
Ketorolac: see Toradol
Kidney, Illegal Trafficking: V15#3
Kidney Disease: V6#6
Kidney Failure: V7#3, V11#2 (drug-induced)
National Home Care Program: V4#5
Nursing Home Overcharges: V8#10
Overcharging: V3#6, V3#7, V4#8, V4#10, V5#10, V6#1, V8#4, V9#12
Peer Review Organizations: see Medicare
Quality of Care Hospital: V4#9
Reform: V11#10, V12#8
Respiratory Equipment (Waste): V8#9
Solvency: V12#9, V12#12
Unnecessary Hospitalization: V4#6
Unnecessary Procedures: V4#1
Medigap: see Medicare, Medigap
Mefloquine: see Larium
Mononucleosis: V8#5, V10#9, V10#10
Metoclopramide: see Reglan
Mental Health: V8#5
Mypyap: V7#12
Midwives: V11#1, V11#2, V11#3, see also Community Mental Health Centers
Midwives: V11#11
Milk, Raw: see Raw Milk
Minilaparatomy: V6#2
Minoxidil: see Rogaine
Midwives: V11#11, V11#6, see also Care of the Seriously Mentally Ill
Merc: V11#10
Mergers: see Health Mergers
Meridia: V14#3
Merital: V2#3, V7#3
Methylen Chloride: V2#3
Metoclopramide: see Reglan
Microbes: V14#1
Midazolam: see Versed
Midwifes: V11#11
Milk, Raw: see Raw Milk
Minilaparatomy: V6#2
Minoxidil: see Rogaine
Misoprostol: see Cytotec
Moanal: see Danthron
Mononucleosis: V4#4
Montelukast: see Singulair
Mypap: V7#12

N
Naprosyn: V10#2
Naproxen: V10#8
Narcotics: V4#3, see also Fentanyl, Narcotic Lollipops
Narrow Therapeutic Index: V13#9
National Health Insurance: V8#5,V10#3, V10#12, V11#2, V15#11
AARP Position: see AARP
Clinton Administration Position: V8#12, V9#4, V9#5, V9#6, V9#7, V10#2, V15#2
Congressional Legislation: V7#4, V8#4
Lobbying: V10#11
Plans, Comparisons: V6#3, V9#5, V10#1, V10#11
Single Payor Support: V8#7, V8#12, V9#7,V9#12, V10#1, V10#3, V10#7, V10#9, V10#11, V14#9
State Plans: see Insurance, State Health Plans
National Medical Enterprises: V10#9
National Practitioner Data Bank: V5#12, V6#3, V6#11, V8#3, V9#8, V10#7
Needle Contamination: V11#8
Needle Exchange Programs: V12#3, V12#11
Nestor, John: V15#6
Niacin: V6#11
Niacin (Sustained Release): V10#4
Nicotine Gum: V4#12
Nicotine Patch: V8#7
Nitroprusside (Nipride): V6#4
Nolvadex: V4#7, V10#8 (correction), V14#12, V15#6
Noise: V3#9
Nomifensine: see Mirtal
Nonsteroidal anti-inflammatory drugs (NSAIDs): V6#6, V9#9, see also individual drug name
Normodyne: see Labetalol
North American Free Trade Agreement, Effects on Health and Safety Regulation: V9#3
Nurse Practitioners: V8#10
Nurses (and Managed Care): V15#5
Nursing Homes: Care:V11#9
Improper Drug Prescribing: V5#1
Nutri/Systems: V14#3

O
Obesity, Children & TV: V1#3
Occupational Safety and Health:
Canadian Plan: V10#5
Health Care Worker: V11#8
Occupational Safety and Health Administration:
V1#3, V4#7, V5#9, V10#3, V10#10
Enforcement: V15#7, V15#10
Safety Bingo: V10#10
Older Adults, Drug Use: V4#6, V4#9, V5#2, V6#8, V6#11, V7#8, V8#3
Olestra: V12#3
Ortho Pharmaceutical Corporation: V11#4
Orudis: V2#3
Osteoarthritis: V14#6
Osteoporosis: V3#5, V3#6, V4#5, V6#11, V11#4, V15#4
Outpatient Commitment: V11#9
Over-the-Counter Drugs:
Switch from prescription: V6#9
Capsules: V7#4
Vs. On the Street: V13#6
Oxazepam: see Serax

P
Pacemakers:
Cellular Phone Interference: V12#7
Defective: V4#10
Electromagnetic Interference: V12#6, V14#11
Respiratory Equipment: V8#9
Unnecessary: V4#4
Pain:
Control After Surgery: V12#9
Management Guidelines: V8#4
Pap Smear: V7#12 (home kit)
Parkinsonism, Drug-Induced: V6#7
Parodel: see Bromocriptine
Patient Cost Sharing: V11#6
Patient Dumping: V4#11, V5#1, V5#9, V7#5, V7#9, V9#6, V10#8, V10#11, V12#4, V14#1
Patient Guide: V11#6, V11#7
Patient Outcome Research Teams (PORTs): V10#11, V10#12
Patient Package Inserts: V11#11
Patients Rights: V6#2, V7#4, V7#11
Patient Safety Act 1994: V10#10
Paxipam: V4#3, V3#4
Pedicle Screws: V11#1
Peer Review Organizations: V3#12, V6#1, V10#3, see also Drug Enforcement Administration, Doctor Sanctions, and Medicare Doctors Sanctioned
Pepper Commission Report: V6#5
Persian Gulf War: V7#1, V7#2
Pertussis Vaccine: V4#5
Pesticides: V7#2
Peterson, Esther: V14#2
Pfizer: V15#9 (ear infections), V15#11 (correction), see also Bjork-Shiley
Pharmaceutical Industry: see Drug Industry
Pharmacists: V11#12
Phenacetin: V7#3
Phenergan: V5#9
Phenylpropanolamine (PPA): V7#1
Philip, Bobbi: V15#10
Philip Morris: V4#2, V5#12, V10#12
Physician: see Doctor
Physio-Control: V9#10
Pilot Fatigue: V8#5, V11#12
Piroxicam: see Fendelle
Plants, Toxic: V8#4
Playground Safety: V6#11
Play Sand, Dangers: see Sand
Poisonings: V13#12
Polls: V10#5
PORTs: see Patient Outcome Research Teams
Potassium: V4#9
Pottery, Irradiated: V8#9
Preparations: see Centrax
Preparation H: V8#5
Prescription: see Drug, Prescription
Pressure Ulcers: V12#11
Prevention/Primary Care: V6#1
Prinivil: V5#10
Product Safety, Alert: V6#10, V6#11, V7#5, V7#7, V7#11, V8#2, V8#4, V8#5, V8#8, V8#11, V9#2, V9#5, V9#8, V9#11, V10#2, V10#5, V10#8, V10#11, V11#2, V11#5, V11#8, V11#11, V12#1, V12#2, V12#5, V12#7, V12#11, V13#2, all issues beginning with V13#3
Project Censored: V9#3, V11#5,V12#5
Progestagen: V5#9
Propoxyphene: see Darvon
Propulsid: V11#3
Mistakes Kept Secret

She filed suit against the surgeon and hospital. They denied the charges. Her lawyer says most cases are settled and kept secret. "The medical profession seems to like to keep the errors that are made a secret to maintain the faith in the profession," said attorney Andrew Meyer.

That's why consumer advocates say the report's call for mandatory reporting of medical errors will likely face stiff resistance from doctors and hospitals.

But the Institute of Medicine says it is important not to blame individual doctors and hospital workers for errors, but to set up systems that stop mistakes from occurring in the first place.

One of the best systems is Brigham and Women's Hospital in Boston. There, all doctors enter their orders in a computer. This prevents mistakes caused by doctors' bad handwriting—like one that a jury found actually led to a patient's death in Texas.

Hospital Errors Leave Dozens Dead

But the computer does much more, including checking the doctor's order automatically against the patient's history. The report said systems like Brigham and Women's are necessary to help create a new culture of safety. Cases like Larviere's show it is long overdue.

OUTRAGE from page 16
Study Shows Widespread Medical Errors

The following is reprinted from a report done by NBC Nightly News, with Bob Baxell reporting, on November 29, 1999.

Nov. 29—In a blistering report released Monday, a prestigious medical group said America's entire health care system needs "dramatic changes" to cut the enormous number of deaths and injuries from medical errors.

The group said hospitals should report mistakes to the federal government—not keep them secret as they often do now.

"For too long medical errors in hospitals and elsewhere have been buried and it is long overdue that they need to be reported to public agencies," said Dr. Sid Wolfe of Public Citizen, a consumer watchdog group.

Experts say between 44,000 and 98,000 Americans die from mistakes every year in hospitals alone. That makes hospital errors the eighth leading cause of death—actually ahead of traffic accidents, breast cancer and AIDS. The report from the Institute of Medicine, a division of the National Academy of Sciences, said the numbers could be cut sharply. It sets as a "minimum goal a 50 percent reduction in errors over five years."

Leading Causes of Death

According to the Institute of Medicine's figures, medical mistakes could rank eighth among the nation's leading causes of death. Other studies double that estimate, placing it above accidents as a killer of Americans.

Errors like the one that happened to Kim Larvie. Last year she entered the hospital for simple, routine surgery to remove varicose veins from her leg. But she says the surgeon mistakenly cut a key artery. Now she is severely disabled with a portion of one foot amputated.

"Before it happened, I was a very independent woman. I did everything. I came and went as I pleased," said Larvie.